Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director · President and CEO | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 269,747 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Grant · Acquired 4,920 · Balance 271,950 F1: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. Row 2 · 2026-05-14 · Sale · Disposed 2,203 · Balance 269,747 F2: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
F2: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 155 · Balance 1,323 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 2 · 2025-06-02 · Disposition to issuer · Disposed 1,323 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 20:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,203 | $9.50 | $20,928.50 |
DisclosureSEC source: 0001193125-26-226613 · ownership.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,747 F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 4,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-226613 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,950 F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 12,361 | $9.41 | $116,310.83 |
DisclosureSEC source: 0001804460-26-000003 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,030 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 81,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-042799 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,391 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:29 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 114,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-241471 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,331 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,257 | $6.43 | $8,082.51 |
DisclosureSEC source: 0001193125-25-205052 · ownership.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,046 F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:35 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-205052 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,303 F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 21:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock | 1,323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081108 · ownership.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4 · price: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081108 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,323 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| May 06, 2025 Filed May 7, 2025 21:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 236 | $7.12 | $1,680.32 |
DisclosureSEC source: 0000950170-25-065884 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,503 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 20:59 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 245 | $3.74 | $916.30 |
DisclosureSEC source: 0000950170-25-051658 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,739 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.74 to $3.86, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:27 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 11,694 | $6.29 | $73,555.26 |
DisclosureSEC source: 0000950170-25-034736 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,984 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:48 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0000950170-25-032297 · ownership.xml · derivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-27 F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F3 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:48 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032297 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,678 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026. F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,099 | $0.65 | $2,664.35 |
DisclosureSEC source: 0000950170-25-014491 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,120,158 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,055 | $0.78 | $3,175.07 |
DisclosureSEC source: 0000950170-25-002819 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124,257 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 21:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,620 | $0.81 | $2,932.20 |
DisclosureSEC source: 0000950170-24-133689 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,128,312 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 49,850 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001562180-24-007607 · primarydocument.xml · derivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,850 Underlying: Common Stock · 49,850 shares Expires 2034-11-06 F2 · derivative.exercise_date: This option vests 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007607 · primarydocument.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,563 F1 · security: These restricted stock units for common stock vest 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,675 | $0.91 | $3,346.46 |
DisclosureSEC source: 0000950170-24-122274 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,131,932 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.9101 to $0.9350, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 20:44 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,607 | $0.88 | $3,171.64 |
DisclosureSEC source: 0000950170-24-113263 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,135,607 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,667 | $0.72 | $2,646.84 |
DisclosureSEC source: 0000950170-24-104033 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,139,214 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:31 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,608 | $0.93 | $3,355.08 |
DisclosureSEC source: 0000950170-24-094087 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,142,881 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,616 | $0.85 | $3,077.22 |
DisclosureSEC source: 0000950170-24-082417 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146,489 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,592 | $0.99 | $3,556.08 |
DisclosureSEC source: 0000950170-24-069856 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,150,105 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:56 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,576 | $1.13 | $4,040.88 |
DisclosureSEC source: 0000950170-24-054686 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,697 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,563 | $1.29 | $4,596.27 |
DisclosureSEC source: 0000950170-24-042350 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,157,273 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 21:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,573 | $1.30 | $4,644.90 |
DisclosureSEC source: 0000950170-24-027153 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,160,836 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.30, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon | 19,374 | $1.20 | $23,248.80 |
DisclosureSEC source: 0000950170-24-025188 · ownership.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,164,409 F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon | 80,470 | $1.17 | $94,149.90 |
DisclosureSEC source: 0000950170-24-025188 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183,783 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 442,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023281 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,264,253 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,012 | $1.59 | $6,365.04 |
DisclosureSEC source: 0000950170-24-012824 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 821,453 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:43 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007583 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 825,465 F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 02:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,114 | $0.82 | $3,373.48 |
DisclosureSEC source: 0000950170-24-003177 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 783,465 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 22:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,622 | $0.79 | $2,861.38 |
DisclosureSEC source: 0001209191-23-057465 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 787,579 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 22:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,606 | $0.92 | $3,318.60 |
DisclosureSEC source: 0001209191-23-054626 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,201 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 20:46 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,589 | $1.27 | $4,558.03 |
DisclosureSEC source: 0001209191-23-052215 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794,807 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 20:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 64 | $1.32 | $84.48 |
DisclosureSEC source: 0000950170-23-046721 · ownership.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 798,396 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 20:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,558 | $1.33 | $4,732.14 |
DisclosureSEC source: 0000950170-23-046721 · ownership.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 798,460 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:02 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,722 | $1.72 | $6,401.84 |
DisclosureSEC source: 0001209191-23-045045 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 802,018 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 21:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,538 | $1.72 | $6,085.36 |
DisclosureSEC source: 0001209191-23-041635 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 805,740 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,536 | $2.24 | $7,922.05 |
DisclosureSEC source: 0001209191-23-035057 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 809,278 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $2.24 to $2.325, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,805 | $3.35 | $12,752.84 |
DisclosureSEC source: 0000899243-23-012353 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 812,814 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.37, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,497 | $3.97 | $13,883.09 |
DisclosureSEC source: 0001209191-23-023378 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 816,619 F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Options (Right to buy) · Derivative | 7,500 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001562180-23-003435 · primarydocument.xml · derivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2033-04-03 F2 · derivative.exercise_date: This option vests ratably over three years in annual installments commencing on April 3, 2023. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 4,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003435 · primarydocument.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,663 F1 · shares: These restricted stock units for common stock vest ratably over three years in annual installments commencing on April 3, 2023. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,506 | $3.16 | $11,078.96 |
DisclosureSEC source: 0001209191-23-016700 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,116 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 33,033 | $3.03 | $100,063.56 |
DisclosureSEC source: 0001209191-23-014838 · doc4.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823,622 F2 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 252,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014838 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,655 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,950 | $3.40 | $13,430.00 |
DisclosureSEC source: 0001209191-23-007772 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,655 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.